

## Xspray - Virtual Capital Markets Day today at 14.00 CET

**Xspray Pharma (Nasdaq Stockholm: XSPRAY) will host a virtual Capital Markets Day today, June 25, at 14.00-15:30 CET. Theme of the day will be how Xspray's product candidate HyNap-Dasa can pave the way for a number of followers based on the company's technology platform.**

Program (approximate time):

14:00 Xspray's operations and remaining development steps for HyNap-Dasa  
- *Per Andersson, CEO*

Intellectual property and patent strategy  
- *Christer Hällgren, Head of IP*

14:45 Existing and potential portfolio of amorphous PKI's  
- *Per Andersson, CEO*

Experiences from the market  
- *Mark Aikman, Syneos Health*

Sprycel's market and the potential for HyNap-Dasa  
- *Mark Brimble, Globe Life Sciences*

15:05 Studio discussion and Q&A session  
- *Guest: Ulrik Trattner, Equity analyst at Carnegie*

The Capital Markets Day is moderated by Charlotte Stjerngren at Cord Communications and will be held in English.

The Capital Markets Day can be seen via Xspray's website: [www.xspraypharma.com](http://www.xspraypharma.com). It will be possible to submit questions to the company before and during the presentations via e-mail to [event@xspray.com](mailto:event@xspray.com).

Welcome!

**For further information, please contact:**

---

Per Andersson, CEO, Xspray Pharma AB  
Phone: +46 (0) 706 88 23 48  
E-mail: [per.andersson@xspray.com](mailto:per.andersson@xspray.com)

## About Xspray Pharma

---

Xspray Pharma AB (publ) is a product development company with multiple product candidates in clinical development. Xspray uses its innovative, patented RightSize technology to develop improved and generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The segment is the second largest in oncology, and drug prices are very high.

The company's innovative technology allows Xspray Pharma to gain entry as the first competitor to today's original drugs before the secondary patents expire. Xspray's goal is to become the leader in the development of improved drugs or generic versions of PKIs already marketed for the treatment of cancer, which numbered to 54 in December 2019. The company's leading product candidates, HyNap-Dasa, HyNap-Sora and HyNap-Nilo, are stable amorphous versions of the three blockbuster cancer drugs Sprycel® (dasatinib), Nexavar® (sorafenib) and Tassigna® (nilotinib), respectively. The launch of the first product candidate, HyNap-Dasa, is planned to take place in 2021. The substance patent for the original drug Sprycel® (dasatinib) expires at the end of 2020, and the secondary patents in 2026, which offers Xspray's HyNap-Dasa a period of five years of semi-exclusivity before other competitors gain access to the market.

The company has patented manufacturing technology, equipment and the resulting products. The shares in Xspray Pharma are traded on Nasdaq Stockholm.

[www.xspraypharma.com](http://www.xspraypharma.com)

## Attachments

---

[Xspray - Virtual Capital Markets Day today at 14.00 CET](#)